Results 1 to 10 of about 105,303 (279)

Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease [PDF]

Frontiers in Immunology, 2018
Acute graft-vs.-host disease (aGVHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), accounting for substantial morbidity and mortality associated with this treatment modality.
Nina C. Zitzer, Nina C. Zitzer, Ramiro Garzon, Parvathi Ranganathan   +3 more
doaj   +3 more sources

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report [PDF]

Journal of Hematology & Oncology, 2016
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication.
Enrico Maffini, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Ilaria Buondonno, Dario Ferrero, Mario Boccadoro, Chiara Dellacasa, Alessandro Busca, Domenico Novero, Benedetto Bruno   +10 more
doaj   +3 more sources

Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial.

JAMA Oncol, 2023
Importance Chronic graft-vs-host disease (GVHD) limits the long-term benefit of haploidentical hematopoietic stem cell transplant (HSCT). This clinical trial evaluated repeated infusions of umbilical cord mesenchymal stem cells (MSCs) during the early ...
Huang R, Chen T, Wang S, Wang J, Su Y, Liu J, Zhang Y, Ma X, Wen Q, Kong P, Zhang C, Gao L, Zhong JF, Gao L, Zhang X.   +14 more
europepmc   +2 more sources

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.

JAMA Netw Open, 2023
Key Points Question Are antibiotics and antibiotic exposure timeframes associated with acute graft-vs-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT)?
Rashidi A, Gao F, Fredricks DN, Pergam SA, Mielcarek M, Milano F, Sandmaier BM, Lee SJ.   +7 more
europepmc   +2 more sources

Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model [PDF]

Frontiers in Immunology, 2017
BackgroundGraft-vs-host disease (GVHD) is a major complication of allogenic bone marrow transplantation (BMT). Targeting costimulatory molecules with antagonist antibodies could dampen the excessive immune response that occurs, while preserving the ...
Aude Burlion, Simon Brunel, Nicolas Y. Petit, Daniel Olive, Gilles Marodon   +4 more
doaj   +2 more sources

Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease

Frontiers in Immunology, 2019
Graft vs. host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Damage to the gastrointestinal (GI) tract from acute GVHD is a particularly serious event that can result in ...
Clint Piper, William R. Drobyski, William R. Drobyski   +2 more
doaj   +2 more sources

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant [PDF]

Journal of Hematology & Oncology, 2016
BackgroundPersons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia interventions are at high risk of a second relapse.
Chen‐Hua Yan, Yu Wang, Jingzhi Wang, Yu‐Hong Chen, Yao Chen, Feng‐Rong Wang, Yuqian Sun, Xiao‐Dong Mo, Wei Han, Huan Chen, Xiaohui Zhang, Lan‐Ping Xu, Kai‐Yan Liu, Xiao‐Jun Huang   +13 more
openalex   +2 more sources

Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high‐risk cancer population with ...
Asmita Mishra, Ram Thapa, Kevin Bigam, Martine Extermann, Rawan Faramand, Farhad Khimani, Xuefeng Wang, Vickie Baracos, Joseph A. Pidala   +8 more
doaj   +2 more sources

Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance

Frontiers in Immunology, 2019
Graft-vs.-host disease (GVHD) remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Hongshuang Yu, Yuanyuan Tian, Ying Wang, Shin Mineishi, Yi Zhang, Yi Zhang   +5 more
doaj   +2 more sources

Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease

Frontiers in Immunology, 2019
Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders.
Govindarajan Thangavelu, Bruce R. Blazar
doaj   +2 more sources